JAGX - Jaguar Health, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2400
+0.0010 (+0.42%)
At close: 4:00PM EST

0.24 -0.00 (-1.04%)
After hours: 5:37PM EST

Stock chart is not supported by your current browser
Previous Close0.2390
Open0.2400
Bid0.22 x 1300
Ask0.24 x 1300
Day's Range0.2301 - 0.2401
52 Week Range0.1150 - 6.6000
Volume644,229
Avg. Volume419,640
Market Cap7.24M
Beta (3Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-4.28
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • ACCESSWIRE27 days ago

    With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product

    SAN FRANCISCO, CA / ACCESSWIRE / January 24, 2019 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Mytesi® (crofelemer) has been added to the formulary for Florida's AIDS Drug Assistance Program (ADAP). As a result of this addition, based on data from healthcare research firm Decision Resource Group, approximately 86% of ADAP-eligible US lives now have access to Mytesi, Jaguar's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

  • ACCESSWIRE29 days ago

    Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale

    SAN FRANCISCO, CA / ACCESSWIRE / January 22, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably ...

  • ACCESSWIRElast month

    Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes

    SAN FRANCISCO, CA / ACCESSWIRE / January 9, 2019 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that a leading equine facility has placed the first order for the first-generation of Equilevia™, the Company's non-prescription, personalized, premium product for total gut health in high-performance equine athletes. As is common practice in the world of horse racing, the identity of the facility is not being disclosed. Equilevia contains ingredients isolated and purified from the medicinal Croton lechleri tree, which is sustainably harvested from the rainforest.

  • ACCESSWIRElast month

    Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates

    SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced commercial sales updates today for the fourth quarter ended December 31, 2018.

  • ACCESSWIRE2 months ago

    Jaguar Health to Present at Biotech Showcase 2019 in San Francisco

    SAN FRANCISCO, CA / ACCESSWIRE / January 3, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Lisa Conte, Jaguar's president and chief executive officer, will present at the annual Biotech Showcase™ conference to be held in San Francisco, California on January 7 - 9, 2019. Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

  • ACCESSWIRE2 months ago

    Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance

    SAN FRANCISCO, CA / ACCESSWIRE / January 2, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, ...

  • ACCESSWIRE2 months ago

    Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer

    SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2018 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it has engaged T.R. Winston & Company, LLC (''T.R. Winston'') to provide strategic advice with respect to collaboration, licensing and development activities in support of Mytesi® and crofelemer. Mytesi is FDA-approved for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS who are on antiretroviral therapy.

  • ACCESSWIRE3 months ago

    Jaguar Health, Inc. Reports Third-Quarter 2018 Results

    SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported third quarter 2018 results and issued the following highlights. Mytesi Net Product Revenue: Mytesi gross sales in the third quarter of 2018 were approximately $1.6 million, and Mytesi net sales were approximately $1.1 million, an increase of 242% and 154% of gross and net sales, respectively, over the third quarter of 2017.

  • ACCESSWIRE3 months ago

    Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th

    Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to Review Q3 Results and Provide Updates Regarding Mytesi ® Commercial, Educational & Product Development Activities ...

  • ACCESSWIRE4 months ago

    The Brilliance Behind a Global Operator of Crypto Exchanges BitMax: Understanding the Trans-Fee Mining Model

    NEW YORK, NY / ACCESSWIRE / October 29, 2018 / As the demand for digital and crypto-assets grows, the long-term success of trading platforms is dependent on several factors including architecture design, ...

  • ACCESSWIRE4 months ago

    Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th

    SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it expects to file its third-quarter 2018 financial results on Wednesday, November 14, 2018 on Form 10-Q with the U.S. Securities and Exchange Commission. The Company will host a conference call on Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to discuss third-quarter results as well as current and planned commercial, educational and product development activities related to Mytesi (crofelemer), Jaguar's first-in-class, FDA-approved anti-secretory human prescription drug.

  • ACCESSWIRE4 months ago

    Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida

    SAN FRANCISCO, CA / ACCESSWIRE / October 24, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, ...

  • ACCESSWIRE5 months ago

    Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering

    SAN FRANCISCO, CA / ACCESSWIRE / October 2, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten public offering of 15,000,001 total shares of its common stock (or common stock equivalents), at a public offering price of $0.60 per share, for gross proceeds of approximately $9.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Jaguar. Jaguar has granted the underwriter a 30-day option to purchase up to an aggregate of 2,250,000 additional shares of its common stock to cover over-allotments, if any.

  • ACCESSWIRE5 months ago

    These Biotech and Cannabis Stocks Are Skyrocketing

    HENDERSON, NV / ACCESSWIRE / September 26, 2018 / A fascinating biotechnology firm PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the last month going from a low of $0.0039 to a high of over ...

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Jaguar Health and TG Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...

  • ACCESSWIRE5 months ago

    Knight Therapeutics and Jaguar Health Announce Strategic Partnership

    Knight Receives License to Mytesi ® and Related Products in Canada and Israel MONTREAL, QC and SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2018 / Knight Therapeutics Inc. (TSX: GUD) (" Knight"), ...

  • ACCESSWIRE7 months ago

    New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time

    SAN FRANCISCO, CA / ACCESSWIRE / July 24, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), announced today the results of an analysis conducted to examine whether the rate of HIV-associated diarrhea has changed over time. The analysis of data, sourced from the National Institutes of Health (NIH) clinicaltrials.gov database, revealed that 18% of HIV patients experience diarrhea and the rates have not declined significantly over time. The analysis includes data from 38 U.S. clinical trials from 2008-2016 in more than 21,000 patients.

  • ACCESSWIRE7 months ago

    Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).

  • ACCESSWIRE7 months ago

    Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference

    Presentation Will Cover New Data on the Incidence and Prevalence of Diarrhea in HIV Clinical Trials in the Recent Post-Combined Antiretroviral Therapy (cART) Era SAN FRANCISCO, CA / ACCESSWIRE / July 16, ...

  • ACCESSWIRE7 months ago

    Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates

    SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced financial updates today for the second quarter ended June 30, 2018. Achieved 125% growth in gross sales of Mytesi for the first six-months of 2018 versus the same period in 2017, and 120% growth in gross sales of Mytesi in the second quarter of 2018 compared to the second quarter of 2017. Continued expansion of the U.S. Napo direct sales organization through the hire of sales representatives with extensive HIV-related experience.